Debanjana Chatterjee
Stock Analyst at Jones Trading
(3.77)
# 748
Out of 5,182 analysts
17
Total ratings
85.71%
Success rate
26.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Initiates: Buy | $11 | $3.66 | +200.55% | 1 | Apr 10, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $25 → $24 | $13.33 | +80.05% | 1 | Mar 19, 2026 | |
| NTLA Intellia Therapeutics | Upgrades: Buy | $29 | $14.26 | +103.37% | 3 | Mar 4, 2026 | |
| ARMP Armata Pharmaceuticals | Initiates: Buy | $15 | $11.69 | +28.31% | 1 | Jan 5, 2026 | |
| SYRE Spyre Therapeutics | Upgrades: Buy | $64 | $63.27 | +1.15% | 2 | Dec 1, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $46 | $41.77 | +10.13% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $16.50 | +45.45% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $5.42 | +398.15% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $3.04 | +1,182.89% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $19.59 | +53.14% | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $12.76 | +80.25% | 1 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $27.88 | +64.99% | 1 | Sep 19, 2024 |
AbCellera Biologics
Apr 10, 2026
Initiates: Buy
Price Target: $11
Current: $3.66
Upside: +200.55%
Trevi Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $25 → $24
Current: $13.33
Upside: +80.05%
Intellia Therapeutics
Mar 4, 2026
Upgrades: Buy
Price Target: $29
Current: $14.26
Upside: +103.37%
Armata Pharmaceuticals
Jan 5, 2026
Initiates: Buy
Price Target: $15
Current: $11.69
Upside: +28.31%
Spyre Therapeutics
Dec 1, 2025
Upgrades: Buy
Price Target: $64
Current: $63.27
Upside: +1.15%
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $41.77
Upside: +10.13%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $16.50
Upside: +45.45%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $5.42
Upside: +398.15%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $3.04
Upside: +1,182.89%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $19.59
Upside: +53.14%
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $12.76
Upside: +80.25%
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $27.88
Upside: +64.99%